<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:55:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10308298" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10308298</identifier>
        <datestamp>2023-06-30</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id>
              <journal-title-group>
                <journal-title>JAMA Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2168-622X</issn>
              <issn pub-type="epub">2168-6238</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10308298</article-id>
              <article-id pub-id-type="pmcid">PMC10308298</article-id>
              <article-id pub-id-type="pmc-uid">10308298</article-id>
              <article-id pub-id-type="pmid">37378974</article-id>
              <article-id pub-id-type="pmid">37378974</article-id>
              <article-id pub-id-type="doi">10.1001/jamapsychiatry.2023.1947</article-id>
              <article-id pub-id-type="publisher-id">yoi230041</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="domain" specific-use="print">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-first">
                  <subject>Online First</subject>
                </subj-group>
                <subj-group subj-group-type="allowCommenting">
                  <subject>Comments</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis</article-title>
                <subtitle>The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial</subtitle>
                <alt-title alt-title-type="headline">Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at High Risk of Psychosis</alt-title>
                <alt-title alt-title-type="running-head">Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at High Risk of Psychosis</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>McGorry</surname>
                    <given-names>Patrick D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mei</surname>
                    <given-names>Cristina</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Amminger</surname>
                    <given-names>G. Paul</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <degrees>(Habil)</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yuen</surname>
                    <given-names>Hok Pan</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kerr</surname>
                    <given-names>Melissa</given-names>
                  </name>
                  <degrees>LLM</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spark</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <degrees>BPsych</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wallis</surname>
                    <given-names>Nicky</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Polari</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="yoi230041aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baird</surname>
                    <given-names>Shelley</given-names>
                  </name>
                  <degrees>BPsych</degrees>
                  <degrees>BN</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buccilli</surname>
                    <given-names>Kate</given-names>
                  </name>
                  <degrees>BPsych</degrees>
                  <degrees>MPPM</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dempsey</surname>
                    <given-names>Sarah-Jane A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferguson</surname>
                    <given-names>Natalie</given-names>
                  </name>
                  <degrees>MClinPsych</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Formica</surname>
                    <given-names>Melanie</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <degrees>(Psych)</degrees>
                  <degrees>(Hons)</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Krcmar</surname>
                    <given-names>Marija</given-names>
                  </name>
                  <degrees>BSci</degrees>
                  <degrees>(Hons)</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Quinn</surname>
                    <given-names>Amelia L.</given-names>
                  </name>
                  <degrees>BPsych</degrees>
                  <degrees>(Hons)</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mebrahtu</surname>
                    <given-names>Yohannes</given-names>
                  </name>
                  <degrees>MLA</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ruslins</surname>
                    <given-names>Arlan</given-names>
                  </name>
                  <degrees>BPsychSc</degrees>
                  <degrees>(Hons)</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Street</surname>
                    <given-names>Rebekah</given-names>
                  </name>
                  <degrees>LLB</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wannan</surname>
                    <given-names>Cassandra</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dixon</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="yoi230041aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carter</surname>
                    <given-names>Cameron</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi230041aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loewy</surname>
                    <given-names>Rachel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Niendam</surname>
                    <given-names>Tara A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shumway</surname>
                    <given-names>Martha</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nelson</surname>
                    <given-names>Barnaby</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi230041aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi230041aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="yoi230041aff1"><label>1</label>Orygen, Melbourne, Victoria, Australia</aff>
              <aff id="yoi230041aff2"><label>2</label>Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia</aff>
              <aff id="yoi230041aff3"><label>3</label>Orygen Specialist Program, Melbourne, Victoria, Australia</aff>
              <aff id="yoi230041aff4"><label>4</label>Department of Psychiatry, Columbia University, New York, New York</aff>
              <aff id="yoi230041aff5"><label>5</label>Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento</aff>
              <aff id="yoi230041aff6"><label>6</label>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> April 22, 2023.</p>
                <p content-type="published-online"><bold>Published Online:</bold> June 28, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamapsychiatry.2023.1947</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 McGorry PD et al. <italic>JAMA Psychiatry</italic>.</p>
                <corresp id="yoi230041cor1"><bold>Corresponding Author:</bold> Patrick D. McGorry, MD, PhD, Orygen, 35 Poplar Rd, Parkville, VIC 3052, Australia (<email xlink:href="pat.mcgorry@orygen.org.au">pat.mcgorry@orygen.org.au</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Dr McGorry had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr McGorry conceived the study, led the design of the trial, and was the principal investigator.</p>
                <p><italic>Concept and design</italic>: McGorry, Amminger, Yuen, Kerr, Dixon, Carter, Nelson.</p>
                <p><italic>Acquisition, analysis, or interpretation of data</italic>: McGorry, Mei, Amminger, Yuen, Kerr, Spark, Wallis, Polari, Baird, Buccilli, Dempsey, Ferguson, Formica, Krcmar, Quinn, Mebrahtu, Ruslins, Street, Wannan, Loewy, Niendam, Shumway, Nelson.</p>
                <p><italic>Drafting of the manuscript</italic>: McGorry, Mei, Spark, Wannan, Dixon, Carter, Nelson.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content</italic>: McGorry, Amminger, Yuen, Kerr, Wallis, Polari, Baird, Buccilli, Dempsey, Ferguson, Formica, Krcmar, Quinn, Mebrahtu, Ruslins, Street, Wannan, Dixon, Loewy, Niendam, Shumway, Nelson.</p>
                <p><italic>Statistical analysis</italic>: McGorry, Yuen, Wannan.</p>
                <p><italic>Obtained funding</italic>: McGorry, Yuen, Carter, Loewy, Nelson.</p>
                <p><italic>Administrative, technical, or material support</italic>: McGorry, Mei, Spark, Wallis, Polari, Baird, Buccilli, Dempsey, Formica, Krcmar, Quinn, Mebrahtu, Ruslins, Street, Dixon, Carter.</p>
                <p><italic>Supervision</italic>: McGorry, Amminger, Kerr, Spark, Polari, Nelson.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr McGorry reported grants from the National Institute of Mental Health during the conduct of the study; in addition, Dr McGorry had a patent for AU 2015203289 issued, a patent for US 9884034 issued, a patent for US 15/844444 issued, and a patent for CA 2773031 issued; and he has received past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and Pfizer, and honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, Roche, Bristol Meyers Squibb, and Lundbeck. He has received grant funding from the Colonial Foundation, the National Health and Medical Research Council of Australia, Australian Research Council, NARSAD, the Stanley Foundation, NIH, the Wellcome Trust, and the Australian and Victorian governments. Dr Yuen reported grants from National Institutes of Health during the conduct of the study. Dr Spark reported grants from National Institute of Health during the conduct of the study. Dr Buccilli reported grants from National Institute of Health (NIH) during the conduct of the study. Dr Krcmar reported grants from National Institute of Mental Health during the conduct of the study. Dr Ruslins reported grants from NIMH during the conduct of the study. Dr Niendam reported grants from National Institute of Health during the conduct of the study; and owning shares in and being a founder and board member of Safari Health, Inc, outside the submitted work. Dr Shumway reported grants from NIH during the conduct of the study. Dr Nelson reported grants from NIH during the conduct of the study. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> Research reported in this publication was supported by the <funding-source rid="sp1">National Institute of Mental Health</funding-source> under award number 1U01MH105258-01. Dr McGorry is supported by a <funding-source rid="sp2">National Health and Medical Research Council</funding-source> Senior Principal Research Fellowship (1155508). Dr Nelson is supported by a <funding-source rid="sp3">National Health and Medical Research Council</funding-source> Senior Research Fellowship (1137687) and a <funding-source rid="sp4">University of Melbourne</funding-source> Dame Kate Campbell Fellowship. Dr Amminger was supported by <funding-source rid="sp5">National Health and Medical Research Council</funding-source> Senior Research Fellowship (1080963).</p>
                <p><bold>Role of the Funder/Sponsors:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> We thank the young people who participated and their families, as well as the youth advisors and research assistants at Orgyen who assisted with the STEP study: Anthony Couroupis, MPsych (Clin); Magdalene De Rozario, MPsych (Clin); Rachid Ghieh, MClinPsych; and Emily Goss MPsych (Clin).</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-06-28T10:00">
                <day>28</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>28</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>80</volume>
              <issue>9</issue>
              <fpage>875</fpage>
              <lpage>885</lpage>
              <history>
                <date date-type="received">
                  <day>14</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 McGorry PD et al. <italic>JAMA Psychiatry</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamapsychiatry-e231947.pdf">jamapsychiatry-e231947.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2023.1947"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-yoi230041-1">
                  <title>Question</title>
                  <p>What are the optimal type, timing, and sequence of interventions for individuals at ultrahigh risk of psychosis?</p>
                </sec>
                <sec id="ab-yoi230041-2">
                  <title>Findings</title>
                  <p>In this sequential multiple assignment randomized trial including 342 individuals, a specialized psychological intervention (cognitive-behavioral case management [CBCM]) and a psychopharmacological intervention (CBCM and antidepressant medication) were not more efficacious than control conditions in improving remission and functional recovery. Relapse rates among individuals who remitted were high.</p>
                </sec>
                <sec id="ab-yoi230041-3">
                  <title>Meaning</title>
                  <p>The findings of this study show that addition of sequentially more specialized psychosocial and antidepressant treatment for individuals who did not remit did not lead to superior outcomes, underscoring the need for further adaptive trials, treatment innovation, and an extended duration of care for relapse prevention.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This sequential multiple assignment randomized trial evaluates the efficacy of an intervention strategy for individuals at ultrahigh risk of psychosis.</p>
              </abstract>
              <abstract>
                <sec id="ab-yoi230041-4">
                  <title>Importance</title>
                  <p>Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis.</p>
                </sec>
                <sec id="ab-yoi230041-5">
                  <title>Objective</title>
                  <p>To determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis.</p>
                </sec>
                <sec id="ab-yoi230041-6">
                  <title>Design, Setting, and Participants</title>
                  <p>The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited.</p>
                </sec>
                <sec id="ab-yoi230041-7">
                  <title>Interventions</title>
                  <p>Step 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of ω-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months.</p>
                </sec>
                <sec id="ab-yoi230041-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Global Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-Åsberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates.</p>
                </sec>
                <sec id="ab-yoi230041-9">
                  <title>Results</title>
                  <p>The sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission).</p>
                </sec>
                <sec id="ab-yoi230041-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments.</p>
                </sec>
                <sec id="ab-yoi230041-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02751632" ext-link-type="uri">NCT02751632</ext-link></p>
                </sec>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source id="sp1">National Institute of Mental Health</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp2">National Health and Medical Research Council</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp3">National Health and Medical Research Council</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp4">University of Melbourne</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp5">National Health and Medical Research Council</funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-YOI230041">
              <title>Introduction</title>
              <p>First-episode psychosis is typically preceded by a prodrome characterized by nonspecific and attenuated psychotic symptoms and functional impairment. Ultrahigh risk criteria were introduced to prospectively identify this prodromal period.<sup><xref rid="yoi230041r1" ref-type="bibr">1</xref></sup> Despite more than 50 ultrahigh risk treatment studies,<sup><xref rid="yoi230041r2" ref-type="bibr">2</xref></sup> including a number of high-quality randomized clinical trials, treatment innovation is urgently needed.<sup><xref rid="yoi230041r3" ref-type="bibr">3</xref>,<xref rid="yoi230041r4" ref-type="bibr">4</xref></sup> While pairwise meta-analytic evidence supports the efficacy of cognitive-behavioral interventions in reducing transition to psychosis,<sup><xref rid="yoi230041r4" ref-type="bibr">4</xref>,<xref rid="yoi230041r5" ref-type="bibr">5</xref></sup> network meta-analyses indicate a lack of evidence for the superiority of any 1 type of intervention.<sup><xref rid="yoi230041r5" ref-type="bibr">5</xref>,<xref rid="yoi230041r6" ref-type="bibr">6</xref></sup> However, group-level improvement has been seen in experimental and active control conditions,<sup><xref rid="yoi230041r7" ref-type="bibr">7</xref>,<xref rid="yoi230041r8" ref-type="bibr">8</xref></sup> indicating that a range of treatments impact transition. Improvements in other symptomatic and functional domains have not been established,<sup><xref rid="yoi230041r4" ref-type="bibr">4</xref>,<xref rid="yoi230041r9" ref-type="bibr">9</xref>,<xref rid="yoi230041r10" ref-type="bibr">10</xref>,<xref rid="yoi230041r11" ref-type="bibr">11</xref>,<xref rid="yoi230041r12" ref-type="bibr">12</xref>,<xref rid="yoi230041r13" ref-type="bibr">13</xref></sup> supporting the need to broaden primary treatment outcomes beyond transition and prioritize functional recovery.<sup><xref rid="yoi230041r4" ref-type="bibr">4</xref>,<xref rid="yoi230041r14" ref-type="bibr">14</xref>,<xref rid="yoi230041r15" ref-type="bibr">15</xref></sup></p>
              <p>Unraveling the heterogeneity in the ultrahigh risk population is paramount to identify subgroups for whom treatments can be tailored.<sup><xref rid="yoi230041r16" ref-type="bibr">16</xref></sup> One potential solution is to develop adaptive treatment strategies that are delivered proactively and sequentially, consistent with clinical staging.<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> Adaptive trial designs are dynamic and enable the treatment type or intensity to be individualized and adjusted in response to treatment progress, thus optimizing outcomes and real-world implementation.<sup><xref rid="yoi230041r17" ref-type="bibr">17</xref></sup> This approach also enhances sample enrichment by addressing issues in the ultrahigh risk field, notably low transition to psychosis rates.<sup><xref rid="yoi230041r18" ref-type="bibr">18</xref>,<xref rid="yoi230041r19" ref-type="bibr">19</xref></sup> That is, individuals who do not respond to simple initial interventions may constitute a subgroup at increased risk of poor clinical outcome.<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref>,<xref rid="yoi230041r20" ref-type="bibr">20</xref></sup></p>
              <p>The current study (Staged Treatment in Early Psychosis [STEP]) aimed to evaluate the outcomes of a sequential multiple assignment randomized clinical trial (SMART) comprising support and problem solving (SPS), cognitive-behavioral case management (CBCM), and fluoxetine for individuals at ultrahigh risk for psychosis.<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> These treatments and their sequence were selected due to their potential benefits and safety profile.<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref>,<xref rid="yoi230041r21" ref-type="bibr">21</xref>,<xref rid="yoi230041r22" ref-type="bibr">22</xref></sup> The sequential treatment strategy, which examined the efficacy of escalating the intensity and duration of treatment for individuals who did not remit on a randomized basis,<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> was expected to produce superior outcomes over 12 months than single-phase trials. Hypotheses were as follows:</p>
              <list list-type="simple">
                <list-item>
                  <p>Hypothesis 1. Open-label SPS would produce a remission rate of 50% (step 1), based on modeling using previous randomized clinical trial data.<sup><xref rid="yoi230041r8" ref-type="bibr">8</xref></sup></p>
                </list-item>
                <list-item>
                  <p>Hypothesis 2a. CBCM would result in significantly better functional outcome than SPS (step 2).</p>
                </list-item>
                <list-item>
                  <p>Hypothesis 2b. In the CBCM group, baseline cognitive biases or vulnerabilities would predict remission and clinical outcome (including functioning) and</p>
                </list-item>
                <list-item>
                  <p>Hypothesis 2c. In the CBCM group, participants with better outcomes and those who remitted would show significantly greater change on these variables than those with worse outcomes and those who did not remit.</p>
                </list-item>
                <list-item>
                  <p>Hypothesis 3. Antidepressant medication (when added to background CBCM) would result in significantly better clinical outcomes than placebo (step 3).</p>
                </list-item>
                <list-item>
                  <p>Hypothesis 4. In those who remitted to step 1 and 2 treatments (SPS and CBCM), a maintenance treatment of SPS would result in a significantly lower rate of relapse than monitoring.</p>
                </list-item>
              </list>
            </sec>
            <sec id="H1-2-YOI230041">
              <title>Methods</title>
              <sec id="H2-1-YOI230041">
                <title>Study Design and Setting</title>
                <p>The SMART design comprised 3 steps: open-label SPS (6 weeks), SPS vs CBCM (20 weeks), and CBCM with fluoxetine vs CBCM with placebo (26 weeks) (eFigure 1 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 1</xref>). Assessments occurred at baseline and weeks 4, 6 (step 1), 12, 24 (step 2), 36, and 52 (step 3) (see <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 1</xref> for the schedule of assessments). The trial was conducted at the Personal Assessment and Crisis Evaluation (PACE) clinic at Orygen, a youth mental health service and research center,<sup><xref rid="yoi230041r23" ref-type="bibr">23</xref></sup> and at Orygen’s 4 headspace centers (youth-friendly enhanced primary care centers).<sup><xref rid="yoi230041r24" ref-type="bibr">24</xref></sup> Enrollment occurred between April 2016 and January 2019. The study was approved by the Melbourne Health Human Research Ethics Committee. The study protocol<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> is available in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 1</xref>. Baseline data have been reported previously.<sup><xref rid="yoi230041r20" ref-type="bibr">20</xref></sup> The study followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.</p>
              </sec>
              <sec id="H2-2-YOI230041">
                <title>Participants</title>
                <p>Individuals seeking treatment were eligible for trial inclusion if they were aged 12 to 25 years, met ultrahigh risk criteria,<sup><xref rid="yoi230041r25" ref-type="bibr">25</xref></sup> spoke adequate English to understand the information and consent form and the questions involved in the clinical instruments, and were able to provide informed consent (including parental or guardian consent for those younger than 18 years). Exclusion criteria were previous psychotic episode of 1 week or longer; attenuated psychotic symptoms only present during acute intoxication; organic brain disease known to cause psychotic symptoms; metabolic, endocrine, or other physical illness; serious developmental disorder; and history of developmental delay or intellectual disability.<sup><xref rid="yoi230041r20" ref-type="bibr">20</xref></sup> Participants taking antidepressant or antipsychotic medication were excluded if medication could not be discontinued at study entry.</p>
                <p>Participants were screened using a standardized clinical assessment and the Prodromal Questionnaire-16 (PQ-16).<sup><xref rid="yoi230041r26" ref-type="bibr">26</xref></sup> For those who scored 6 or higher positive symptoms, had a family history of psychotic disorder, or for whom there was a clinical impression of possibly meeting ultrahigh risk criteria, ultrahigh risk status was determined using the Comprehensive Assessment of At-Risk Mental States (CAARMS),<sup><xref rid="yoi230041r25" ref-type="bibr">25</xref></sup> Social and Occupational Functioning Assessment Scale (SOFAS),<sup><xref rid="yoi230041r27" ref-type="bibr">27</xref></sup> SCID-II Schizotypal PD, and Family History Index.<sup><xref rid="yoi230041r20" ref-type="bibr">20</xref></sup></p>
              </sec>
              <sec id="H2-3-YOI230041">
                <title>Randomization</title>
                <p>Randomization was based on computer-generated treatment allocations prepared by independent personnel. Participants who met remission criteria at the end of step 1 were randomized to SPS or monitoring; those who did not remit were randomized to CBCM or SPS. Assessors were blind to treatment allocation. Participants in the nonremission arm of the trial were randomized a second time based on remission status at the end of step 2. Those who remitted were randomized to SPS or monitoring; those who did not were randomized to CBCM with fluoxetine or CBCM with placebo, stratified by Montgomery-Åsberg Depression Rating Scale (MADRS) total score (lower than 21 vs 21 or higher). In step 3, assessors and participants were blind to treatment allocation.</p>
              </sec>
              <sec id="H2-4-YOI230041">
                <title>Treatments</title>
                <sec id="H3-1-YOI230041">
                  <title>Monitoring</title>
                  <p>Clinicians monitored participants’ mental state and risk at 3, 6, 9, and 12 months postentry to step 1. Any deterioration in mental health was appropriately managed.</p>
                </sec>
                <sec id="H3-2-YOI230041">
                  <title>SPS</title>
                  <p>Manualized supportive counseling and problem-solving strategies were delivered within a positive psychology framework. Sessions were 30 to 50 minutes (weekly to fortnightly). In the relapse prevention and remission trial arm, participants received monthly SPS for up to 12 months.</p>
                </sec>
                <sec id="H3-3-YOI230041">
                  <title>CBCM</title>
                  <p>CBCM, a specialized manualized psychosocial intervention, consisted of cognitive behavioral therapy (CBT) provided within a case management framework.<sup><xref rid="yoi230041r28" ref-type="bibr">28</xref></sup> CBT included psychoeducation, behavioral strategies or experiments, and cognitive restructuring targeting attenuated psychotic symptoms, stress management, negative symptoms or depression, and other comorbidities. Case management support addressed current practical and social issues. Sessions were 30 to 50 minutes (weekly or as needed). See eMethods 1 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref> for further details on SPS and CBCM.</p>
                </sec>
                <sec id="H3-4-YOI230041">
                  <title>Medications</title>
                  <p>Step 3 comprised 1 capsule of fluoxetine, 20 mg per day, or placebo, increasing to 40 mg per day or 2 placebo capsules after 6 weeks if clinical response was insufficient as judged by the treating psychiatrist. At 12 weeks, a fast-fail option was available for participants who had deteriorated or had not responded to treatment. Through a shared decision-making process, participants chose to either continue as randomized, increase the fluoxetine or placebo dosage, or receive an add-on of low-dose antipsychotic medication (quetiapine, 50-300 mg per day, or aripiprazole, 10-30 mg per day) or long-chain ω-3 fatty acids (2.8 g per day of marine fish oil in 4 × 0.7-g capsules containing approximately 1.4 g eicosapentanoic and docosahexanoic acid).</p>
                </sec>
              </sec>
              <sec id="H2-5-YOI230041">
                <title>Outcome Measures</title>
                <p>For power purposes and sample size calculation,<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> the primary outcome chosen was functioning at 6 months (end of step 2), measured by the Global Functioning: Social and Role scales.<sup><xref rid="yoi230041r29" ref-type="bibr">29</xref></sup> However, an important perspective for some research considerations is the pattern of remission across all steps over 12 months. Remission criteria, reflecting symptomatic and functional remission, were a global rating scale or frequency score less than 3 on the CAARMS unusual thought content, nonbizarre ideas, and perceptual abnormalities subscales; a global rating scale score less than 4 or frequency score less than 3 on the disorganized speech subscale; and improvement of 5 or more points on the SOFAS compared with baseline or a SOFAS score of 70 or higher. Remission rates reported reflect sustained remission at the end of a step; that is, remission criteria were met at weeks 4 and 6 for step 1, 12 and 24 for step 2, and 36 and 52 for step 3. Relapse was recorded if remission criteria were no longer met at 6 or 12 months.</p>
                <p>Other outcome measures included the Brief Psychiatric Rating Scale (BPRS);<sup><xref rid="yoi230041r30" ref-type="bibr">30</xref></sup> Scale for the Assessment of Negative Symptoms (SANS);<sup><xref rid="yoi230041r31" ref-type="bibr">31</xref></sup> MADRS;<sup><xref rid="yoi230041r32" ref-type="bibr">32</xref></sup> Assessment of Quality of Life (AQoL-8D); SOFAS; transition to psychosis, defined as daily positive psychotic symptoms for 1 week or longer (CAARMS); and Davos Assessment of Cognitive Biases Scale (DACOBS; validated self-report measure of cognitive problems and biases).<sup><xref rid="yoi230041r33" ref-type="bibr">33</xref></sup></p>
                <p>Therapy sessions were audio recorded with consent and independently rated for fidelity. Based on the minimum number of sessions provided for each treatment at each step,<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> adherence in the nonremission arm was defined as 3 or more sessions of SPS (step 1), 9 or more of SPS (step 2), and 6 or more of CBCM (steps 2 and 3). For the remission arm, the number of sessions was 5 or more for SPS and 2 or more for monitoring (for those who remitted at step 1), 3 or more for SPS, and 1 or more for monitoring (for those who remitted at step 2). Medication adherence was based on participants’ estimation of dose taken (&lt;50%, 51%-75%, and &gt;75%) and capsule count, with adherence achieved when both were greater than 75%. Adverse events were assessed at baseline and each visit.</p>
              </sec>
              <sec id="H2-6-YOI230041">
                <title>Statistical Analysis</title>
                <p>The study was powered to detect a small to medium effect size (Cohen <italic>f</italic>) of 0.18 on the primary 6-month functional outcome (end of step 2) and a medium effect size of 0.29 at 12 months (end of step 3) (Nelson et al<sup><xref rid="yoi230041r15" ref-type="bibr">15</xref></sup> and <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 1</xref>). The intent-to-treat approach was used with missing data handled using multiple imputation (eMethods 2 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). Complete-case (ie, only including participants with nonmissing data) and per-protocol analyses (ie, only including participants who adhered to the allocated treatments) were also conducted. For continuous outcomes, a general linear model analysis compared the groups concerned with the relevant original baseline score (ie, day 1) as a covariate. χ<sup>2</sup> test compared remission rates between treatments. Relapse rates were examined using the Fisher exact test for individuals who remitted at step 1 and logistic regression for those who remitted at step 2. Relapse at 12 months was the dependent variable, and group factors were SPS vs CBCM and SPS vs monitoring. The interaction term between these 2 factors was included. Transition to psychosis rates were examined using Kaplan-Meier estimation and log-rank test. The correlation between DACOBS and clinical measures and 6-month remission status was examined using Pearson correlation and point-biserial correlation, respectively. The <italic>t</italic> test compared change in DACOBS total score (6-month score minus baseline) between individuals who did and did not remit at step 2. Generalized linear mixed effects logistic regression estimated the probability of treatment fidelity with agreement between allocated treatment and rater-determined treatment as the dependent variable and therapy type (SPS or CBCM) as a fixed factor and participants and clinicians as random factors. Significance level was set at .05.</p>
              </sec>
            </sec>
            <sec id="H1-3-YOI230041">
              <title>Results</title>
              <sec id="H2-7-YOI230041">
                <title>Participant Flow</title>
                <p>Of 1343 individuals considered, 342 were included (198 female; mean [SD] age, 17.7 [3.1] years) (<xref rid="yoi230041t1" ref-type="table">Table 1</xref>). Assignment to each treatment arm according to remission status is shown in <xref rid="yoi230041f1" ref-type="fig">Figure 1</xref>. Participants (n = 342) and nonparticipants (n = 787, excluding those who did not meet ultrahigh risk criteria or represent the target population) did not significantly differ according to age and sex. The frequency of concomitant medication for the entire sample (n = 342) over the 24-month study period was 33.0% (n = 113) for antidepressants, 4.7% (n = 16) for antipsychotics, 6.7% (n = 23) for anxiolytics, 8.8% (n = 30) for sedatives, and 78.9% (n = 270) for other medications.</p>
                <table-wrap position="float" id="yoi230041t1">
                  <?xpp 1.5col?>
                  <label>Table 1. </label>
                  <caption>
                    <title>Sample Demographic Characteristics at Baseline</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="69.39%" span="1"/>
                    <col width="30.61%" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"/>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Total sample (N = 342)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD; range), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17.7 (3.1; 12.5-25.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">198 (57.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">144 (42.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Currently in education, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">245 (71.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">95 (27.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Highest level of education, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Primary school</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Year 7-10</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">160 (46.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Year 11-12</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">101 (29.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TAFE</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (8.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Undergraduate degree</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (9.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Postgraduate degree</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (2.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Current employment, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unemployed</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">218 (63.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Casual paid</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">70 (20.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Part-time paid</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (7.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Full-time paid</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (3.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Casual unpaid</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Part-time unpaid</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">CAARMS severity score,<xref rid="yoi230041t1n1" ref-type="table-fn"><sup>a</sup></xref> mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unusual thought content</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonbizarre ideas</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.9 (1.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Perceptual abnormalities</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.1 (1.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Disorganized speech</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.7 (1.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">CAARMS frequency score,<xref rid="yoi230041t1n2" ref-type="table-fn"><sup>b</sup></xref> mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unusual thought content</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.4 (1.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonbizarre ideas</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.0 (1.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Perceptual abnormalities</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Disorganized speech</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">CAARMS composite score,<xref rid="yoi230041t1n3" ref-type="table-fn"><sup>c</sup></xref> mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Attenuated positive psychotic severity score</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34.6 (16.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Negative symptoms score (SANS total score), mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18.4 (11.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">General psychopathology (BPRS total score), mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">44.6 (8.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Depressive symptoms (MADRS total score), mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23.5 (9.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Global Functioning: Social, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.6 (1.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Global Functioning: Role, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.3 (1.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Social and occupational functioning (SOFAS), mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">56.7 (11.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Recruitment site, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Headspace</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">310 (90.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PACE</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 (9.4)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: BPRS, Brief Psychiatric Rating Scale; CAARMS, Comprehensive Assessment of At-Risk Mental States; MADRS, Montgomery-Åsberg Depression Rating Scale; PACE, Personal Assessment and Crisis Evaluation; SANS, Scale for the Assessment of Negative Symptoms; SPS, support and problem solving; SOFAS, Social and Occupational Functioning Assessment Scale; TAFE, Technical and Further Education.</p>
                    <fn id="yoi230041t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Severity score ranges from 0 (never or absent) to 6 (psychotic and severe).</p>
                    </fn>
                    <fn id="yoi230041t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Frequency score ranges from 0 (absent) to 6 (continuous).</p>
                    </fn>
                    <fn id="yoi230041t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Composite score is the sum of the product of severity and frequency of the 4 subscales (unusual thought content, nonbizarre ideas, perceptual abnormalities, and disorganized speech).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="yoi230041f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>CONSORT Diagram</title>
                  </caption>
                  <graphic xlink:href="jamapsychiatry-e231947-g001" position="float"/>
                </fig>
                <p>Discontinuation rates were 17.8% (61 of 342; step 1), 47.7% (134 of 281; step 2), and 38.4% (53 of 138; step 3). Reasons for discontinuation are listed in eTable 1 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>. Of 76 participants lost to follow-up, 19 (25.0%) met remission criteria at the last available follow-up, 36 (47.4%) did not meet remission criteria, and 21 (27.6%) were undeterminable due to no follow-up. Among those who discontinued for other reasons (n = 172), 32 (18.6%) met remission criteria at the last assessment before treatment discontinuation, 117 (68.0%) did not meet criteria, and 23 (13.4%) were undeterminable. The following results are from the intent-to-treat analysis with multiple imputation.</p>
                <sec id="H3-5-YOI230041">
                  <title>Hypothesis 1: Remission Rates</title>
                  <p>Remission rates (ie, sustained remission) across treatment arms at the end of steps 1, 2, and 3 were 8.5%, 10.3%, and 11.4%, respectively. The overall remission rate (ie, sustained remission at the end of at least one step) was 27.2%. There were no significant differences in remission rates between treatments at the end of step 2 (9.8% [CBCM] vs 10.7% [SPS]; <italic>P</italic> = .84) and step 3 (10.6% [CBCM with fluoxetine] vs 12.2% [CBCM with placebo]; <italic>P</italic> = .67). Remission rates of those recruited at PACE vs headspace did not significantly differ at step 1 (4.0% vs 9.0%), 2 (4.6% vs 10.9%), or 3 (14.6% vs 11.1%).</p>
                </sec>
                <sec id="H3-6-YOI230041">
                  <title>Hypothesis 2a: Effect of CBCM on Functioning and Clinical Measures</title>
                  <p>For the primary outcome, intent-to-treat analysis revealed no significant difference in mean scores on the Global Functioning: Social and Role scales between SPS and CBCM at 6 months (<xref rid="yoi230041t2" ref-type="table">Table 2</xref> and eFigure 1 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). There was no significant difference between SPS and CBCM on any clinical measure (<xref rid="yoi230041t2" ref-type="table">Table 2</xref> and eFigures1, 2A, and 3A in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                  <table-wrap position="float" id="yoi230041t2">
                    <label>Table 2. </label>
                    <caption>
                      <title>General Linear Model Analysis Comparing Cognitive-Behavioral Case Management (CBCM) and Support and Problem Solving (SPS) at 6 Months and CBCM With Fluoxetine and CBCM With Placebo at 12 Months<xref rid="yoi230041t2n5" ref-type="table-fn"><sup>e</sup></xref></title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="9.07%" span="1"/>
                      <col width="0.31%" span="1"/>
                      <col width="8.71%" span="1"/>
                      <col width="9.72%" span="1"/>
                      <col width="9.72%" span="1"/>
                      <col width="7.3%" span="1"/>
                      <col width="5.02%" span="1"/>
                      <col width="12.69%" span="1"/>
                      <col width="9.9%" span="1"/>
                      <col width="9.9%" span="1"/>
                      <col width="7.3%" span="1"/>
                      <col width="5.21%" span="1"/>
                      <col width="5.15%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="3" valign="top" align="left" scope="col" colspan="1"/>
                          <th rowspan="3" colspan="2" valign="top" align="left" scope="colgroup">Treatment</th>
                          <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Step 2 (mean No. = 159 SPS, 153 CBCM)<sup>d</sup></th>
                          <th colspan="6" valign="top" align="left" scope="colgroup" rowspan="1">Step 3 (mean No. = 139 fluoxetine; 141 placebo)<sup>d</sup></th>
                        </tr>
                        <tr>
                          <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SE)</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Effect size</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="yoi230041t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Treatment</th>
                          <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SE)</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Effect size</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="yoi230041t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="yoi230041t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Baseline</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Month 6</th>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Baseline</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Month 12</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">GF: social</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.6 (0.10)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.7 (0.17)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.63</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.27)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.03</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.85</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.83</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.10)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.17)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.6 (0.12)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.4 (0.29)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">GF: role</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.1 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.19)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.03</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.85</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.2 (0.15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.29)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.01</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.93</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.90</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.4 (0.12)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.6 (0.19)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.3 (0.15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.5 (0.30)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BPRS total score</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">45.7 (0.70)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">42.9 (0.82)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.02</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.90</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">45.8 (0.81)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">41.6 (1.24)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.15</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.37</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.90</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">44.8 (0.67)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">42.3 (0.82)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">45.9 (0.84)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">43.1 (1.27)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">SANS total score</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18.7 (0.92)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">17.2 (1.05)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.06</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.65</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19.3 (1.06)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">16.6 (1.35)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.08</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.60</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.93</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18.8 (0.89)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">17.8 (1.13)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19.0 (1.08)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">17.4 (1.50)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">MADRS total score</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">23.5 (0.77)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">20.3 (0.96)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.58</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">24.8 (0.91)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18.7 (1.39)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.11</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.52</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.87</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">24.9 (0.76)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">20.2 (0.95)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">24.5 (0.93)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19.8 (1.41)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">SOFAS</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">56.3 (0.96)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">60.1 (1.21)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.04</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.75</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">56.0 (1.10)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">60.0 (1.70)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.03</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.84</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.75</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">56.7 (0.91)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">59.8 (1.22)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">56.2 (1.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">59.6 (1.63)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">AQoL total score</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">54.1 (0.99)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">58.2 (1.10)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.60</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">52.6 (1.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">61.4 (1.53)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.10</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.54</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.83</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">51.6 (0.96)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">57.2 (1.17)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">52.0 (1.22)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">59.9 (1.60)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">DACOBS total score</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">171.3 (2.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">163.3 (2.8)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.11</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.43</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">171.2 (3.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">152.4 (4.3)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.08</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.61</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.84</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">171.5 (2.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">160.8 (3.1)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">173.8 (3.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">156.7 (4.1)</td>
                        </tr>
                        <tr>
                          <td colspan="13" valign="top" align="left" scope="col" rowspan="1">
                            <bold>CAARMS, severity</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">UTC</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.1 (0.18)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.05</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.68</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.17)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.24)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.12</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.42</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.88</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.19)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.9 (0.17)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.2 (0.24)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">NBI</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.0 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.18)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.62</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.0 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.25)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.14</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.39</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.47</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.0 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.3 (0.18)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.1 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.3 (0.24)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">PA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.1 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.18)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.10</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.45</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.3 (0.14)</td>
                          <td valign="middle" align="center" rowspan="1" colspan="1">2.6 (0.23)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.01</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.93</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.58</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.3 (0.11)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.18)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.2 (0.15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.25)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">DS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.10)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.15)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.04</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.80</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.12)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.21)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.02</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.92</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.99</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.09)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.8 (0.14)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.7 (0.11)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.21)</td>
                        </tr>
                        <tr>
                          <td colspan="13" valign="top" align="left" scope="col" rowspan="1">
                            <bold>CAARMS, frequency</bold>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">UTC</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.0 (0.18)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.01</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.93</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.1 (0.24)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.03</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.85</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.64</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.3 (0.14)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.9 (0.19)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.1 (0.25)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">NBI</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.2 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.18)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.02</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.87</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.1 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.4 (0.25)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.04</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.78</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.59</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.0 (0.13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.19)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.3 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.25)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">PA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.4 (0.12)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.17)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.61</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.13)</td>
                          <td valign="middle" align="center" rowspan="1" colspan="1">2.4 (0.24)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.07</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.69</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.95</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.10)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.18)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.14)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.25)</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1">DS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.16)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.20)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.06</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">0.68</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM + placebo</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.17)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.8 (0.26)</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">−0.04</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.81</td>
                          <td rowspan="2" valign="middle" align="center" colspan="1">.87</td>
                        </tr>
                        <tr>
                          <td colspan="2" valign="top" align="left" scope="row" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1">CBCM</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.5 (0.15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.19)</td>
                          <td valign="top" colspan="1" align="left" rowspan="1">CBCM + fluoxetine</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.6 (0.18)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0.26)</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Abbreviations: AQoL, Assessment of Quality of Life; BPRS, Brief Psychiatric Rating Scale; CAARMS, Comprehensive Assessment of At-Risk Mental States; DACOBS, Davos Assessment of Cognitive Biases Scale; DS, disorganized speech; GF, Global Functioning Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; NBI, nonbizarre ideas; PA, perceptual abnormalities; SANS, Scale for the Assessment of Negative Symptoms; SOFAS, Social and Occupational Functioning Assessment Scale; UTC, unusual thought content.</p>
                      <fn id="yoi230041t2n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>Comparing SPS and CBCM with baseline score as a covariate.</p>
                      </fn>
                      <fn id="yoi230041t2n2">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>Comparing CBCM + placebo and CBCM + fluoxetine with baseline score as a covariate.</p>
                      </fn>
                      <fn id="yoi230041t2n3">
                        <label>
                          <sup>c</sup>
                        </label>
                        <p>Interaction between step 2 treatment (SPS/CBCM) and step 3 treatment (CBCM + placebo / CBCM + fluoxetine) with baseline score as a covariate.</p>
                      </fn>
                      <fn id="yoi230041t2n4">
                        <label>
                          <sup>d</sup>
                        </label>
                        <p>The mean sample sizes for each group over the multiple imputations.</p>
                      </fn>
                      <fn id="yoi230041t2n5">
                        <label>
                          <sup>e</sup>
                        </label>
                        <p>Missing data handled by multiple imputation.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="H3-7-YOI230041">
                  <title>Hypotheses 2b and 2c: Effect of Baseline Cognitive Biases or Vulnerabilities on Remission and Treatment Outcome</title>
                  <p>While this hypothesis was intended to be restricted to the CBCM group, CBCM did not produce superior outcomes or greater improvement on cognitive biases or vulnerabilities than SPS (<xref rid="yoi230041t2" ref-type="table">Table 2</xref>; eFigure 1 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). Hence, the following analyses include both the CBCM and SPS groups.</p>
                  <p>The correlation between baseline DACOBS total and 6-month outcomes and between change in DACOBS total and change in outcomes among those who did not remit at step 1 is presented in eTable 2 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>. Baseline DACOBS was significantly correlated with BPRS (<italic>r</italic>, 0.15), SANS (<italic>r</italic>, 0.26), AQoL (<italic>r</italic>, −0.27), and SOFAS (<italic>r</italic>, −0.18) at 6 months. The correlation between baseline DACOBS and 6-month remission status was nonsignificant (<italic>r</italic>, −0.11; <italic>P</italic> = .12). At 6 months, improvement in DACOBS showed a significant correlation with improvements in BPRS (<italic>r</italic>, 0.31), MADRS (<italic>r</italic>, 0.26), and AQoL (<italic>r</italic>, −0.38). Participants who remitted at the end of step 2 (n = 26) showed a larger nonsignificant mean improvement in DACOBS than those who did not (n = 148; −13.0 vs −7.8; <italic>P</italic> = .38).</p>
                </sec>
                <sec id="H3-8-YOI230041">
                  <title>Hypothesis 3: Effect of Antidepressant Medication on Clinical Outcome</title>
                  <p>Both treatment arms (CBCM with fluoxetine and CBCM with placebo) showed improvement by the end of step 3, with no significant difference on any measure (<xref rid="yoi230041t2" ref-type="table">Table 2</xref>; <xref rid="yoi230041f2" ref-type="fig">Figure 2</xref>; eFigures 2B and 3B in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). The interaction effect between MADRS score (&lt;21 vs ≥21) and treatment (fluoxetine vs placebo) showed that the effect of fluoxetine did not significantly differ according to MADRS score on any measure, indicating that fluoxetine was not more effective for those with severe depression. Mean scores of the fast-fail group are shown in eTable 3 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p>
                  <fig position="float" id="yoi230041f2" fig-type="figure">
                    <label>Figure 2. </label>
                    <caption>
                      <title>Changes in Mean Symptom and Functioning Scores From Baseline to the End of Step 3</title>
                      <p>Circles represent individual participant data. Fluoxetine or placebo commenced at 6 months (start of step 3). AQoL indicates assessment of quality of life; BPRS, Brief Psychiatric Rating Scale; CBCM, cognitive-behavioral case management; DACOBS, Davos Assessment of Cognitive Biases Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; SOFAS, Social and Occupational Functioning Assessment Scale.</p>
                    </caption>
                    <graphic xlink:href="jamapsychiatry-e231947-g002" position="float"/>
                  </fig>
                </sec>
                <sec id="H3-9-YOI230041">
                  <title>Hypothesis 4: Relapse Rates and Outcomes of Participants Who Remitted</title>
                  <p>Six-month relapse rates were higher in the SPS group (59.8%) than monitoring (16.9%) among participants who remitted at step 1 (<italic>P</italic> = .03). This difference was not maintained at 12 months (65.1% vs 58.3%, respectively; <italic>P</italic> = .72). At the end of step 2, there was no significant difference in 12-month relapse rates (37.7% for SPS vs 47.5% for monitoring; <italic>P</italic> = .32).</p>
                  <p>Six-month SOFAS scores significantly differed between SPS and monitoring among participants who remitted at step 1 (effect size, 0.91; 95% CI, 0.95-19.6; <italic>P</italic> = .03) (eTable 4 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). The direction of the effect favored the monitoring group. At 12 months, there were no significant differences between the two groups on any measure among those who remitted at steps 1 or 2 (eTables 4-5 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                </sec>
              </sec>
              <sec id="H2-8-YOI230041">
                <title>Transition to Psychosis</title>
                <p>The Kaplan-Meier–estimated 12-month transition rate was 13.5% (95% CI, 9.1-18.0). The log-rank test indicated no significant difference between groups at 6 and 12 months (<xref rid="yoi230041t3" ref-type="table">Table 3</xref>). The 12-month transition rate was 3.3% (95% CI, 0.3-7.0) for those who remitted at any stage and 17.4% (95% CI, 12.5-21.9) for those who did not (<italic>P</italic> = .001).</p>
                <table-wrap position="float" id="yoi230041t3">
                  <label>Table 3. </label>
                  <caption>
                    <title>Kaplan-Meier Estimated Transition Rates at 6 and 12 Months With Missing Data Handled by Multiple Imputation</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="19.8%" span="1"/>
                    <col width="19.79%" span="1"/>
                    <col width="13.03%" span="1"/>
                    <col width="13.03%" span="1"/>
                    <col width="27.11%" span="1"/>
                    <col width="7.24%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" colspan="2" valign="top" align="left" scope="colgroup"/>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean No. over multiple imputations</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Estimated transition rate, % (95% CI)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="yoi230041t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Cases</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Transitions</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">6 mo</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="2" valign="top" align="left" scope="row" colspan="1"> Step 1 nonremission</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">159</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.9 (2.9-10.7)</td>
                        <td rowspan="2" valign="middle" align="center" colspan="1">.52</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="1" align="left" scope="row" rowspan="1">CBCM</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">153</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.6 (4.1-13.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">12 mo</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="2" valign="top" align="left" scope="row" colspan="1"> Step 1 remission</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Monitoring</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.3 (0-19.6)</td>
                        <td rowspan="2" valign="middle" align="center" colspan="1">.61</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="1" align="left" scope="row" rowspan="1">SPS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.2 (0-21.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" valign="top" align="left" scope="row" colspan="1"> Step 2 nonremission</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Placebo</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">141</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.3 (9.2-21.0)</td>
                        <td rowspan="2" valign="middle" align="center" colspan="1">.51</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Fluoxetine</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">139</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16.1 (9.8-22.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" valign="top" align="left" scope="row" colspan="1"> Step 2 remission</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Monitoring</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.9 (0-18.3)</td>
                        <td rowspan="2" valign="middle" align="center" colspan="1">.66</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="1" align="left" scope="row" rowspan="1">SPS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.7 (0-20.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: CBCM, cognitive-behavioral case management; SPS, support and problem solving.</p>
                    <fn id="yoi230041t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p><italic>P</italic> value comparing the survival curves of the treatments concerned using log-rank test.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-9-YOI230041">
                <title>Overall Treatment Effect and Complete-Case and Per-Protocol Analyses</title>
                <p>Across the entire sample, small to medium effect sizes were found at 6 and 12 months on measures of symptoms and functioning (eTable 6 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). The complete-case and per-protocol analyses yielded results consistent with intent-to-treat findings (eTables 7-15 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
              </sec>
              <sec id="H2-10-YOI230041">
                <title>Treatment Adherence and Fidelity</title>
                <p>The mean (SD) number of sessions attended was 2.3 (1.5) and 5.7 (3.9) for SPS at steps 1 and 2, respectively, and 6.2 (3.7) at step 2 and 6.0 (4.2) at step 3 for CBCM. A total of 199 recordings (65 participants; 24 clinicians) were rated for fidelity, a mean (SD) of 3.1 (2.1) per participant and 8.3 (9.3) per clinician. The probability that each type of treatment was given as intended was estimated to be 0.95 (95% CI, 0.88-0.98) for SPS and 0.59 (95% CI, 0.51-0.67) for CBCM, indicating higher fidelity to SPS (<italic>P</italic> &lt; .001). Adherence was low to moderate for SPS, moderate for CBCM, and low for fluoxetine and placebo (eTable 16 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>). While adherence with SPS in participants in the step 2 nonremission arm was significantly lower than with CBCM (33 of 127 [26.0%] vs 68 of 127 [53.5%]), when adherence with both treatments was defined similarly (6 or more sessions), adherence with SPS increased (61 of 127 [48.0%]) and did not significantly differ from CBCM. When the per-protocol analyses were repeated with a 6 or more session adherence level for SPS, the results were similar to those obtained using a 9 or more session cut point and the conclusions remained the same.</p>
              </sec>
              <sec id="H2-11-YOI230041">
                <title>Adverse Events</title>
                <p>Few adverse and serious adverse events occurred. No significant group differences were observed (eTable 17 in <xref rid="note-YOI230041-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
              </sec>
            </sec>
            <sec id="H1-4-YOI230041">
              <title>Discussion</title>
              <p>This is the first SMART trial to be conducted in the ultrahigh risk population. The primary outcome of functioning at the end of step 2 was selected for sample size and power calculations; however, results should be considered as a whole, spanning all steps. For the primary outcome, there was no difference between CBCM and SPS. While the sample overall showed modest functional and symptomatic improvement over 12 months, remission rates were lower than expected, the transition rate was slightly higher than anticipated, and there was no significant difference between groups on the secondary outcomes. Even when remission was achieved, it was difficult to maintain, and continuing supportive therapy did not reduce relapse rates compared to monitoring. While the monitoring group showed greater improvement in 6-month SOFAS scores than SPS, this was likely due to 4 outliers in the SPS group whose 6-month SOFAS outcomes were worse than the other individuals who remitted at step 1. The findings suggest that enhancing the intensity of treatment with psychological interventions (CBCM) or antidepressant medication in real-world youth mental health services does not produce benefit over continuing simpler care for a longer period. However, some caution is needed given the following caveats.</p>
              <p>First, the bar for remission was high, although appropriately so, requiring sustained symptomatic and functional improvement. If remission had been based on symptomatic improvement only, the overall remission rate would have increased to 41.2% (compared to 27.2%).</p>
              <p>Second, the rate of treatment discontinuation was substantial (18% at step 1, 48% at step 2, and 38% at step 3). However, this rate was comparable to that of the seminal Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial,<sup><xref rid="yoi230041r34" ref-type="bibr">34</xref></sup> albeit with a different population focus.</p>
              <p>Third, adherence to psychological therapy and medication and fidelity to CBCM were suboptimal. These challenges are common in psychotherapy trials.<sup><xref rid="yoi230041r35" ref-type="bibr">35</xref>,<xref rid="yoi230041r36" ref-type="bibr">36</xref>,<xref rid="yoi230041r37" ref-type="bibr">37</xref>,<xref rid="yoi230041r38" ref-type="bibr">38</xref></sup> The very low adherence to fluoxetine (26.8%) led to insufficient power, though its timing (6 months postbaseline) may have been too delayed to protect against transition to psychosis.<sup><xref rid="yoi230041r22" ref-type="bibr">22</xref></sup> Despite the moderate fidelity to CBCM, findings indicate that the greater the change in cognitive biases or vulnerabilities, the greater the clinical improvement across both treatment groups, suggesting the psychological target of CBCM may represent more of an outcome rather than mediating variable. Compared to ultrahigh risk cohorts who received CBCM in specialized services,<sup><xref rid="yoi230041r7" ref-type="bibr">7</xref></sup> the current predominately primary care-based sample showed more modest improvements and a slightly higher transition rate. The therapist team in this study were not expert research therapists as in past studies but a large, diverse group of frontline primary care clinicians who may not have been as capable of fidelity to the therapeutic model. Further examination of the real-world quality of CBCM, particularly in primary care settings, is needed. Extending the involvement of young people with lived experience beyond the design phase throughout the study may have led to higher retention, adherence, and fidelity.</p>
              <p>A positive note is that transition to psychosis was significantly lower among participants who remitted (3.3%) than those who did not (17.4%). While this may indicate that trials with transition as the primary outcome may enroll an enriched sample by filtering out those with early remission, relapse to ultrahigh risk positive status was common. Although all treatment arms showed a trend of symptomatic and functional improvement by the end of steps 2 and 3, improvement was typically modest, slow to emerge, and somewhat fragile. The lack of a no-treatment comparison group makes firm conclusions difficult.</p>
              <p>While some caution is warranted, and needs-based care should continue to be provided to all patients at ultrahigh risk, the findings indicate the need for further sequential randomized trials examining existing treatments with improved adherence and fidelity and for the development of innovative, more effective treatments and enhanced modes of delivery. This could include virtual reality; neurofeedback; higher-fidelity CBT; individual placement and support; biotherapies (eg, cannabidiol,<sup><xref rid="yoi230041r39" ref-type="bibr">39</xref></sup> antiinflammatories, and pomaglumetad methionil<sup><xref rid="yoi230041r40" ref-type="bibr">40</xref></sup>); neuroprotective agents, including low-dose lithium<sup><xref rid="yoi230041r41" ref-type="bibr">41</xref></sup>; and reconsideration of low-dose antipsychotic medication for individuals who do not remit to psychosocial interventions. Attempts to develop new treatments are under way<sup><xref rid="yoi230041r42" ref-type="bibr">42</xref>,<xref rid="yoi230041r43" ref-type="bibr">43</xref>,<xref rid="yoi230041r44" ref-type="bibr">44</xref></sup>; however, we also need to better understand the effective elements<sup><xref rid="yoi230041r45" ref-type="bibr">45</xref></sup> of existing treatments, particularly from a transdiagnostic perspective.<sup><xref rid="yoi230041r46" ref-type="bibr">46</xref>,<xref rid="yoi230041r47" ref-type="bibr">47</xref>,<xref rid="yoi230041r48" ref-type="bibr">48</xref></sup></p>
              <sec id="H2-12-YOI230041">
                <title>Strengths and Limitations</title>
                <p>To our knowledge, this is the largest ultrahigh risk for psychosis trial to date, reflecting the utility of primary care youth mental health platforms, particularly when recruiting medication-naive participants. However, the treatment provided was insufficient for a large proportion of our sample. Despite high dropout rates, the achieved sample sizes (192 at step 2 and 92 at step 3) were similar to original expectations because of the higher than expected nonremission rates. The moderate fidelity to CBCM, the low adherence to medication, and high degree of treatment discontinuation and missing data may have limited the ability to test hypotheses and identify benefits of treatments.</p>
              </sec>
            </sec>
            <sec id="H1-5-YOI230041">
              <title>Conclusions</title>
              <p>Enhancing the intensity of treatment with psychological interventions or medications was challenging to implement with fidelity and adherence in this largely primary care-based sample but nevertheless could not be demonstrated to produce any benefit over and above continuing a simpler form of care. Low remission and high relapse rates confirm the sustained vulnerability and substantial morbidity of the ultrahigh risk population and highlight the need to conduct further adaptive trials, develop new treatments, provide sustained specialist care, and identify subgroups for whom treatments can be tailored.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-YOI230041">
              <title>References</title>
              <ref id="yoi230041r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>McFarlane</surname><given-names>CA</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Patton</surname><given-names>GC</given-names></string-name>, <string-name><surname>Rakkar</surname><given-names>A</given-names></string-name></person-group>. <article-title>Monitoring and care of young people at incipient risk of psychosis</article-title>. <source>Schizophr Bull</source>. <year>1996</year>;<volume>22</volume>(<issue>2</issue>):<fpage>283</fpage>-<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/22.2.283</pub-id><?supplied-pmid 8782287?><pub-id pub-id-type="pmid">8782287</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Addington</surname><given-names>J</given-names></string-name>, <string-name><surname>Farris</surname><given-names>M</given-names></string-name>, <string-name><surname>Devoe</surname><given-names>D</given-names></string-name>, <string-name><surname>Metzak</surname><given-names>P</given-names></string-name></person-group>. <article-title>Progression from being at-risk to psychosis: next steps</article-title>. <source>NPJ Schizophr</source>. <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<fpage>27</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41537-020-00117-0</pub-id><?supplied-pmid 33020486?><pub-id pub-id-type="pmid">33020486</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Mei</surname><given-names>C</given-names></string-name>, <string-name><surname>Hartmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name></person-group>. <article-title>Intervention strategies for ultrahigh risk for psychosis: progress in delaying the onset and reducing the impact of first-episode psychosis</article-title>. <source>Schizophr Res</source>. <year>2021</year>;<volume>228</volume>:<fpage>344</fpage>-<lpage>356</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.schres.2020.12.026</pub-id><?supplied-pmid 33545668?><pub-id pub-id-type="pmid">33545668</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mei</surname><given-names>C</given-names></string-name>, <string-name><surname>van der Gaag</surname><given-names>M</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Preventive interventions for individuals at ultra high risk for psychosis: an updated and extended meta-analysis</article-title>. <source>Clin Psychol Rev</source>. <year>2021</year>;<volume>86</volume>:<elocation-id>102005</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.cpr.2021.102005</pub-id><?supplied-pmid 33810885?><pub-id pub-id-type="pmid">33810885</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Devoe</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Farris</surname><given-names>MS</given-names></string-name>, <string-name><surname>Townes</surname><given-names>P</given-names></string-name>, <string-name><surname>Addington</surname><given-names>J</given-names></string-name></person-group>. <article-title>Interventions and transition in youth at risk of psychosis: a systematic review and meta-analyses</article-title>. <source>J Clin Psychiatry</source>. <year>2020</year>;<volume>81</volume>(<issue>3</issue>):<elocation-id>17r12053</elocation-id>. doi:<pub-id pub-id-type="doi">10.4088/JCP.17r12053</pub-id><?supplied-pmid 32433834?><pub-id pub-id-type="pmid">32433834</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Davies</surname><given-names>C</given-names></string-name>, <string-name><surname>Cipriani</surname><given-names>A</given-names></string-name>, <string-name><surname>Ioannidis</surname><given-names>JPA</given-names></string-name>, <etal/></person-group>. <article-title>Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis</article-title>. <source>World Psychiatry</source>. <year>2018</year>;<volume>17</volume>(<issue>2</issue>):<fpage>196</fpage>-<lpage>209</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wps.20526</pub-id><?supplied-pmid 29856551?><pub-id pub-id-type="pmid">29856551</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Markulev</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial</article-title>. <source>JAMA Psychiatry</source>. <year>2017</year>;<volume>74</volume>(<issue>1</issue>):<fpage>19</fpage>-<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.2902</pub-id><?supplied-pmid 27893018?><pub-id pub-id-type="pmid">27893018</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>LJ</given-names></string-name>, <etal/></person-group>. <article-title>Randomized controlled trial of interventions for young people at ultrahigh risk of psychosis: twelve-month outcome</article-title>. <source>J Clin Psychiatry</source>. <year>2013</year>;<volume>74</volume>(<issue>4</issue>):<fpage>349</fpage>-<lpage>356</lpage>. doi:<pub-id pub-id-type="doi">10.4088/JCP.12m07785</pub-id><?supplied-pmid 23218022?><pub-id pub-id-type="pmid">23218022</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Devoe</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Farris</surname><given-names>MS</given-names></string-name>, <string-name><surname>Townes</surname><given-names>P</given-names></string-name>, <string-name><surname>Addington</surname><given-names>J</given-names></string-name></person-group>. <article-title>Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis</article-title>. <source>Early Interv Psychiatry</source>. <year>2019</year>;<volume>13</volume>(<issue>1</issue>):<fpage>3</fpage>-<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.12677</pub-id><?supplied-pmid 29749710?><pub-id pub-id-type="pmid">29749710</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Devoe</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>A</given-names></string-name>, <string-name><surname>Addington</surname><given-names>J</given-names></string-name></person-group>. <article-title>Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis</article-title>. <source>Schizophr Bull</source>. <year>2018</year>;<volume>44</volume>(<issue>4</issue>):<fpage>807</fpage>-<lpage>823</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbx139</pub-id><?supplied-pmid 29069511?><pub-id pub-id-type="pmid">29069511</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Davies</surname><given-names>C</given-names></string-name>, <string-name><surname>Radua</surname><given-names>J</given-names></string-name>, <string-name><surname>Cipriani</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis</article-title>. <source>Front Psychiatry</source>. <year>2018</year>;<volume>9</volume>:<fpage>187</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2018.00187</pub-id><?supplied-pmid 29946270?><pub-id pub-id-type="pmid">29946270</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Devoe</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Farris</surname><given-names>MS</given-names></string-name>, <string-name><surname>Townes</surname><given-names>P</given-names></string-name>, <string-name><surname>Addington</surname><given-names>J</given-names></string-name></person-group>. <article-title>Interventions and social functioning in youth at risk of psychosis: a systematic review and meta-analysis</article-title>. <source>Early Interv Psychiatry</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>169</fpage>-<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.12689</pub-id><?supplied-pmid 29938910?><pub-id pub-id-type="pmid">29938910</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bosnjak Kuharic</surname><given-names>D</given-names></string-name>, <string-name><surname>Kekin</surname><given-names>I</given-names></string-name>, <string-name><surname>Hew</surname><given-names>J</given-names></string-name>, <string-name><surname>Rojnic Kuzman</surname><given-names>M</given-names></string-name>, <string-name><surname>Puljak</surname><given-names>L</given-names></string-name></person-group>. <article-title>Interventions for prodromal stage of psychosis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2019</year>;<volume>2019</volume>(<issue>11</issue>):<elocation-id>CD012236</elocation-id>. doi:<pub-id pub-id-type="doi">10.4172/2378-5756.1000258</pub-id><?supplied-pmid 31689359?><pub-id pub-id-type="pmid">31689359</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Carrión</surname><given-names>RE</given-names></string-name>, <string-name><surname>McLaughlin</surname><given-names>D</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>TE</given-names></string-name>, <etal/></person-group>. <article-title>Prediction of functional outcome in individuals at clinical high risk for psychosis</article-title>. <source>JAMA Psychiatry</source>. <year>2013</year>;<volume>70</volume>(<issue>11</issue>):<fpage>1133</fpage>-<lpage>1142</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.1909</pub-id><?supplied-pmid 24006090?><pub-id pub-id-type="pmid">24006090</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>HP</given-names></string-name>, <etal/></person-group>. <article-title>Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients</article-title>. <source>Early Interv Psychiatry</source>. <year>2018</year>;<volume>12</volume>(<issue>3</issue>):<fpage>292</fpage>-<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.12459</pub-id><?supplied-pmid 28719151?><pub-id pub-id-type="pmid">28719151</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Markulev</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>The NEURAPRO biomarker analysis: long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youths at ultrahigh risk for psychosis</article-title>. <source>Biol Psychiatry</source>. <year>2020</year>;<volume>87</volume>(<issue>3</issue>):<fpage>243</fpage>-<lpage>252</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2019.08.030</pub-id><?supplied-pmid 31690495?><pub-id pub-id-type="pmid">31690495</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Murphy</surname><given-names>SA</given-names></string-name></person-group>. <article-title>An experimental design for the development of adaptive treatment strategies</article-title>. <source>Stat Med</source>. <year>2005</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1455</fpage>-<lpage>1481</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.2022</pub-id><?supplied-pmid 15586395?><pub-id pub-id-type="pmid">15586395</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hartmann</surname><given-names>JA</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>HP</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <etal/></person-group>. <article-title>Declining transition rates to psychotic disorder in “ultrahigh risk” clients: investigation of a dilution effect</article-title>. <source>Schizophr Res</source>. <year>2016</year>;<volume>170</volume>(<issue>1</issue>):<fpage>130</fpage>-<lpage>136</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.schres.2015.11.026</pub-id><?supplied-pmid 26673973?><pub-id pub-id-type="pmid">26673973</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>HP</given-names></string-name>, <string-name><surname>Berger</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?</article-title><source>Schizophr Bull</source>. <year>2007</year>;<volume>33</volume>(<issue>3</issue>):<fpage>673</fpage>-<lpage>681</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbm015</pub-id><?supplied-pmid 17404389?><pub-id pub-id-type="pmid">17404389</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hartmann</surname><given-names>JA</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <etal/></person-group>. <article-title>Baseline data of a sequential multiple assignment randomized trial (STEP study)</article-title>. <source>Early Interv Psychiatry</source>. <year>2022</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1130</fpage>-<lpage>1142</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.13263</pub-id><?supplied-pmid 35098659?><pub-id pub-id-type="pmid">35098659</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r21">
                <label>21</label>
                <mixed-citation publication-type="webpage"><person-group><collab>Orygen</collab></person-group>. <italic>Treating Depression in Young People: Guidance, Resources and Tools for Assessment and Management</italic>. Published <year>2017</year>. <ext-link xlink:href="https://www.orygen.org.au/Skills-Knowledge/Resources-Training/Resources/Free/Clinical-Practice/Treating-depression-in-young-people-Guidance,-res/orygen_Clinical_practice_guide_depression_in_young.aspx?ext=." ext-link-type="uri">https://www.orygen.org.au/Skills-Knowledge/Resources-Training/Resources/Free/Clinical-Practice/Treating-depression-in-young-people-Guidance,-res/orygen_Clinical_practice_guide_depression_in_young.aspx?ext=.</ext-link></mixed-citation>
              </ref>
              <ref id="yoi230041r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Raballo</surname><given-names>A</given-names></string-name>, <string-name><surname>Poletti</surname><given-names>M</given-names></string-name>, <string-name><surname>Preti</surname><given-names>A</given-names></string-name></person-group>. <article-title>Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? systematic review and meta-analysis</article-title>. <source>Psychol Med</source>. <year>2022</year>;<fpage>1</fpage>-<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291722001428</pub-id><?supplied-pmid 35655405?><pub-id pub-id-type="pmid">35655405</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cotton</surname><given-names>SM</given-names></string-name>, <string-name><surname>Filia</surname><given-names>KM</given-names></string-name>, <string-name><surname>Ratheesh</surname><given-names>A</given-names></string-name>, <string-name><surname>Pennell</surname><given-names>K</given-names></string-name>, <string-name><surname>Goldstone</surname><given-names>S</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Early psychosis research at Orygen, the National Centre of Excellence in Youth Mental Health</article-title>. <source>Soc Psychiatry Psychiatr Epidemiol</source>. <year>2016</year>;<volume>51</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00127-015-1140-0</pub-id><?supplied-pmid 26498752?><pub-id pub-id-type="pmid">26498752</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rickwood</surname><given-names>D</given-names></string-name>, <string-name><surname>Paraskakis</surname><given-names>M</given-names></string-name>, <string-name><surname>Quin</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Australia’s innovation in youth mental health care: the headspace centre model</article-title>. <source>Early Interv Psychiatry</source>. <year>2019</year>;<volume>13</volume>(<issue>1</issue>):<fpage>159</fpage>-<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.12740</pub-id><?supplied-pmid 30311423?><pub-id pub-id-type="pmid">30311423</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>HP</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <etal/></person-group>. <article-title>Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States</article-title>. <source>Aust N Z J Psychiatry</source>. <year>2005</year>;<volume>39</volume>(<issue>11-12</issue>):<fpage>964</fpage>-<lpage>971</lpage>. doi:<pub-id pub-id-type="doi">10.1080/j.1440-1614.2005.01714.x</pub-id><?supplied-pmid 16343296?><pub-id pub-id-type="pmid">16343296</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ising</surname><given-names>HK</given-names></string-name>, <string-name><surname>Veling</surname><given-names>W</given-names></string-name>, <string-name><surname>Loewy</surname><given-names>RL</given-names></string-name>, <etal/></person-group>. <article-title>The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population</article-title>. <source>Schizophr Bull</source>. <year>2012</year>;<volume>38</volume>(<issue>6</issue>):<fpage>1288</fpage>-<lpage>1296</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbs068</pub-id><?supplied-pmid 22516147?><pub-id pub-id-type="pmid">22516147</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Goldman</surname><given-names>HH</given-names></string-name>, <string-name><surname>Skodol</surname><given-names>AE</given-names></string-name>, <string-name><surname>Lave</surname><given-names>TR</given-names></string-name></person-group>. <article-title>Revising axis V for <italic>DSM-IV</italic>: a review of measures of social functioning</article-title>. <source>Am J Psychiatry</source>. <year>1992</year>;<volume>149</volume>(<issue>9</issue>):<fpage>1148</fpage>-<lpage>1156</lpage>. doi:<pub-id pub-id-type="doi">10.1176/ajp.149.9.1148</pub-id><?supplied-pmid 1386964?><pub-id pub-id-type="pmid">1386964</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r28">
                <label>28</label>
                <mixed-citation publication-type="book"><person-group><collab>The PACE Manual Writing Group</collab></person-group>. <source>The PACE clinic manual: a treatment approach for young people at ultra high risk of psychosis</source>. <publisher-name>Orygen Youth Health</publisher-name>; <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="yoi230041r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cornblatt</surname><given-names>BA</given-names></string-name>, <string-name><surname>Auther</surname><given-names>AM</given-names></string-name>, <string-name><surname>Niendam</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia</article-title>. <source>Schizophr Bull</source>. <year>2007</year>;<volume>33</volume>(<issue>3</issue>):<fpage>688</fpage>-<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbm029</pub-id><?supplied-pmid 17440198?><pub-id pub-id-type="pmid">17440198</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Overall</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gorham</surname><given-names>DR</given-names></string-name></person-group>. <article-title>The brief psychiatric rating scale</article-title>. <source>Psychol Rep</source>. <year>1962</year>;<volume>10</volume>(<issue>3</issue>):<fpage>799</fpage>-<lpage>812</lpage>. doi:<pub-id pub-id-type="doi">10.2466/pr0.1962.10.3.799</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r31">
                <label>31</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Andreasen</surname><given-names>NC</given-names></string-name></person-group>. <source>Scale for the Assessment of Negative Symptoms (SANS)</source>. <publisher-name>University of Iowa</publisher-name>; <year>1983</year>.</mixed-citation>
              </ref>
              <ref id="yoi230041r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Montgomery</surname><given-names>SA</given-names></string-name>, <string-name><surname>Åsberg</surname><given-names>M</given-names></string-name></person-group>. <article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br J Psychiatry</source>. <year>1979</year>;<volume>134</volume>(<issue>4</issue>):<fpage>382</fpage>-<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id><?supplied-pmid 444788?><pub-id pub-id-type="pmid">444788</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>van der Gaag</surname><given-names>M</given-names></string-name>, <string-name><surname>Schütz</surname><given-names>C</given-names></string-name>, <string-name><surname>Ten Napel</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Development of the Davos assessment of cognitive biases scale (DACOBS)</article-title>. <source>Schizophr Res</source>. <year>2013</year>;<volume>144</volume>(<issue>1-3</issue>):<fpage>63</fpage>-<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.schres.2012.12.010</pub-id><?supplied-pmid 23332365?><pub-id pub-id-type="pmid">23332365</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rush</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Trivedi</surname><given-names>MH</given-names></string-name>, <string-name><surname>Wisniewski</surname><given-names>SR</given-names></string-name>, <etal/></person-group>. <article-title>Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report</article-title>. <source>Am J Psychiatry</source>. <year>2006</year>;<volume>163</volume>(<issue>11</issue>):<fpage>1905</fpage>-<lpage>1917</lpage>. doi:<pub-id pub-id-type="doi">10.1176/ajp.2006.163.11.1905</pub-id><?supplied-pmid 17074942?><pub-id pub-id-type="pmid">17074942</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Meyer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Perkins</surname><given-names>SL</given-names></string-name>, <string-name><surname>Brower</surname><given-names>CS</given-names></string-name>, <etal/></person-group>. <article-title>Feasibility of an exercise and CBT intervention for treatment of depression: a pilot randomized controlled trial</article-title>. <source>Front Psychiatry</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>799600</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2022.799600</pub-id><?supplied-pmid 35599775?><pub-id pub-id-type="pmid">35599775</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Prowse</surname><given-names>P-TD</given-names></string-name>, <string-name><surname>Nagel</surname><given-names>T</given-names></string-name>, <string-name><surname>Meadows</surname><given-names>GN</given-names></string-name>, <string-name><surname>Enticott</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Treatment fidelity over the last decade in psychosocial clinical trials outcome studies: a systematic review</article-title>. <source>J Psychiatry</source>. <year>2015</year>;<volume>18</volume>(<issue>2</issue>):<elocation-id>1000258</elocation-id>.</mixed-citation>
              </ref>
              <ref id="yoi230041r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Karas</surname><given-names>S</given-names></string-name>, <string-name><surname>Plankis</surname><given-names>L</given-names></string-name></person-group>. <article-title>Consideration of treatment fidelity to improve manual therapy research</article-title>. <source>J Man Manip Ther</source>. <year>2016</year>;<volume>24</volume>(<issue>4</issue>):<fpage>233</fpage>-<lpage>237</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10669817.2015.1135555</pub-id><?supplied-pmid 27582623?><pub-id pub-id-type="pmid">27582623</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Toomey</surname><given-names>E</given-names></string-name>, <string-name><surname>Hardeman</surname><given-names>W</given-names></string-name>, <string-name><surname>Hankonen</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Focusing on fidelity: narrative review and recommendations for improving intervention fidelity within trials of health behaviour change interventions</article-title>. <source>Health Psychol Behav Med</source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>132</fpage>-<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21642850.2020.1738935</pub-id><?supplied-pmid 34040865?><pub-id pub-id-type="pmid">34040865</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <string-name><surname>Lin</surname><given-names>A</given-names></string-name>, <string-name><surname>Kerr</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Cannabidiol for at risk for psychosis youth: a randomized controlled trial</article-title>. <source>Early Interv Psychiatry</source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>419</fpage>-<lpage>432</lpage>. doi:<pub-id pub-id-type="doi">10.1111/eip.13182</pub-id><?supplied-pmid 34190422?><pub-id pub-id-type="pmid">34190422</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sonnenschein</surname><given-names>SF</given-names></string-name>, <string-name><surname>Grace</surname><given-names>A</given-names></string-name></person-group>. <article-title>Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis</article-title>. <source>Expert Opin Ther Targets</source>. <year>2021</year>;<volume>25</volume>(<issue>1</issue>):<fpage>15</fpage>-<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14728222.2021.1849144</pub-id><?supplied-pmid 33170748?><pub-id pub-id-type="pmid">33170748</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Berger</surname><given-names>GE</given-names></string-name>, <string-name><surname>Wood</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Neuroprotective effects of low-dose lithium in individuals at ultrahigh risk for psychosis. a longitudinal MRI/MRS study</article-title>. <source>Curr Pharm Des</source>. <year>2012</year>;<volume>18</volume>(<issue>4</issue>):<fpage>570</fpage>-<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.2174/138161212799316163</pub-id><?supplied-pmid 22239590?><pub-id pub-id-type="pmid">22239590</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r42">
                <label>42</label>
                <mixed-citation publication-type="webpage"><person-group><collab>National Institutes of Health</collab></person-group>. Accelerating medicines partnership program—schizophrenia. Accessed May 24, 2023. <ext-link xlink:href="https://www.ampscz.org" ext-link-type="uri">https://www.ampscz.org</ext-link></mixed-citation>
              </ref>
              <ref id="yoi230041r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dolgin</surname><given-names>E</given-names></string-name></person-group>. <article-title>Massive NIH-industry project opens portals to target validation</article-title>. <source>Nat Rev Drug Discov</source>. <year>2019</year>;<volume>18</volume>:<fpage>240</fpage>-<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1038/d41573-019-00033-8</pub-id><?supplied-pmid 30936505?><pub-id pub-id-type="pmid">30936505</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gordon</surname><given-names>JA</given-names></string-name>, <string-name><surname>Heinssen</surname><given-names>RK</given-names></string-name></person-group>. <article-title>Collaborative approaches to the clinical high-risk state: from data to mechanism to intervention</article-title>. <source>Biol Psychiatry</source>. <year>2020</year>;<volume>88</volume>(<issue>4</issue>):<fpage>287</fpage>-<lpage>288</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2020.05.027</pub-id><?supplied-pmid 32622464?><pub-id pub-id-type="pmid">32622464</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sebastian</surname><given-names>CL</given-names></string-name>, <string-name><surname>Pote</surname><given-names>I</given-names></string-name>, <string-name><surname>Wolpert</surname><given-names>M</given-names></string-name></person-group>. <article-title>Searching for active ingredients to combat youth anxiety and depression</article-title>. <source>Nat Hum Behav</source>. <year>2021</year>;<volume>5</volume>(<issue>10</issue>):<fpage>1266</fpage>-<lpage>1268</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41562-021-01195-5</pub-id><?supplied-pmid 34621050?><pub-id pub-id-type="pmid">34621050</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Recent meta-analyses in the clinical high risk for psychosis population: clinical interpretation of findings and suggestions for future research</article-title>. <source>Front Psychiatry</source>. <year>2018</year>;<volume>9</volume>:<fpage>502</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2018.00502</pub-id><?supplied-pmid 30369889?><pub-id pub-id-type="pmid">30369889</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Hartmann</surname><given-names>JA</given-names></string-name>, <string-name><surname>Spooner</surname><given-names>R</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>B</given-names></string-name></person-group>. <article-title>Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry</article-title>. <source>World Psychiatry</source>. <year>2018</year>;<volume>17</volume>(<issue>2</issue>):<fpage>133</fpage>-<lpage>142</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wps.20514</pub-id><?supplied-pmid 29856558?><pub-id pub-id-type="pmid">29856558</pub-id></mixed-citation>
              </ref>
              <ref id="yoi230041r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nelson</surname><given-names>B</given-names></string-name>, <string-name><surname>Amminger</surname><given-names>GP</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>A</given-names></string-name>, <string-name><surname>Wood</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Commentary: preventive treatments for psychosis: umbrella review (just the evidence)</article-title>. <source>Front Psychiatry</source>. <year>2020</year>;<volume>11</volume>:<fpage>488</fpage>-<lpage>488</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2020.00488</pub-id><?supplied-pmid 32536883?><pub-id pub-id-type="pmid">32536883</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-YOI230041-1">
              <supplementary-material id="note-YOI230041-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>Trial protocol</p>
                </caption>
                <media xlink:href="jamapsychiatry-e231947-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>eMethods</p>
                  <p>eTable 1. Reasons for treatment discontinuation (%)</p>
                  <p>eTable 2. Pearson correlation between baseline DACOBS total and 6-month outcomes and between change in DACOBS total and change in outcomes (Step 1 non-remitters)</p>
                  <p>eTable 3. 12-month outcomes of the fast-fail group</p>
                  <p>eTable 4. General linear model analysis comparing SPS and monitoring (Step 1 remitters) at 6 and 12 months with data handled using multiple imputation</p>
                  <p>eTable 5. General linear model analysis comparing SPS and monitoring (Step 2 remitters) at 12 months with data handled using multiple imputation</p>
                  <p>eTable 6. Effect sizes (Cohen’s d) at 6 and 12 months across the entire sample</p>
                  <p>eTable 7. Complete-case and per-protocol analysis comparing CBCM and SPS at 6 months</p>
                  <p>eTable 8. Complete-case and per-protocol analysis comparing CBCM+fluoxetine and CBCM+placebo at 12 months</p>
                  <p>eTable 9. Complete-case and per-protocol analysis of remission rates</p>
                  <p>eTable 10. Complete-case and per-protocol analysis comparing relapse rates between SPS and monitoring (Step 1 remitters) at 6 and 12 months</p>
                  <p>eTable 11. Complete-case and per-protocol analysis comparing relapse rates between SPS and monitoring (Step 2 remitters) at 12 months using logistic regression</p>
                  <p>eTable 12. Complete-case and per-protocol analysis comparing SPS and monitoring (Step 1 remitters) at 6 months</p>
                  <p>eTable 13. Complete-case and per-protocol analysis comparing SPS and monitoring (Step 1 remitters) at 12 months</p>
                  <p>eTable 14. Complete-case and per-protocol analysis comparing SPS and monitoring (Step 2 remitters) at 12 months</p>
                  <p>eTable 15. Kaplan-Meier estimated transition rates (complete-case and per-protocol analysis)</p>
                  <p>eTable 16. Treatment adherence rates</p>
                  <p>eTable 17. Adverse events</p>
                  <p>eFigure 1. Changes in mean symptom and functioning scores from baseline to the end of Step 2</p>
                  <p>eFigure 2. Changes in mean CAARMS severity scores from baseline to the end of Step 2 (panel A) and Step 3 (panel B)</p>
                  <p>eFigure 3. Changes in mean CAARMS frequency scores from baseline to the end of Step 2 (panel A) and Step 3 (panel B)</p>
                </caption>
                <media xlink:href="jamapsychiatry-e231947-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>Data sharing statement</p>
                </caption>
                <media xlink:href="jamapsychiatry-e231947-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
